Market capitalization | $377.16m |
Enterprise Value | $363.32m |
EV/Sales (TTM) EV/Sales | 12.38 |
P/S ratio (TTM) P/S ratio | 12.85 |
Dividend yield | 13.31% |
Last dividend (FY24) | $1.86 |
Revenue growth (TTM) Revenue growth | -6.90% |
Revenue (TTM) Revenue | $29.34m |
EBIT (operating result TTM) EBIT | $38.81m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
Mar '24 |
+/-
%
|
||
Revenue | 29 29 |
7%
7%
|
|
Gross Profit | 24 24 |
8%
8%
|
|
EBITDA | 39 39 |
607%
607%
|
EBIT (Operating Income) EBIT | 39 39 |
606%
606%
|
Net Profit | 39 39 |
606%
606%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Tekla Life Sciences Investors operates as a closed-end investment fund or Investment trust. The firm engages in the investment in the life sciences industry. It invests in biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals and healthcare information technology and services. The company was founded on February 20, 1992 and is headquartered in Boston, MA.
Head office | United States |
CEO | Dan Omstead |
Founded | 1992 |
Website | www.teklacap.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.